Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.74 USD | -3.08% | -9.00% | +35.39% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.39% | 278M | |
+3.79% | 43.43B | |
+47.70% | 41.69B | |
+8.16% | 41.31B | |
-10.92% | 27.14B | |
+8.60% | 25.28B | |
-24.77% | 18.47B | |
+31.25% | 12.59B | |
+0.91% | 12.33B | |
+9.21% | 11.03B |
- Stock Market
- Equities
- ENTA Stock
- News Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals : Evercore ISI Starts Enanta Pharmaceuticals at Underperform With $30 Price Target